Interleukin‐1, interleukin‐10 and tumour necrosis factor‐alpha gene polymorphisms in hepatitis C virus infection: an investigation of the relationships with spontaneous viral clearance and response to alpha‐interferon therapy

Constantini, Patricia K.; Wawrzynowicz‐Syczewska, Marta; Clare, Michael; Boroń-Kaczmarska, Anna; McFarlane, Ian G.; Cramp, M.; Donaldson, Peter

doi:10.1034/j.1600-0676.2002.01553.x

Cited by 69 publications

(4 citation statements)

References 43 publications

(63 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results are consistent with those reported by Zein et al [42], but quite different from another study[43]. SNPs at -308 showed inconsistent associations with various HCV outcomes[32],[44],[45]. The -308A promoter variant has been associated with enhanced transcription of TNF-α [12], but other investigations have failed to confirm this finding[46].…”

Section: Discussionsupporting

confidence: 76%

Tumor necrosis factor-alpha-308G/A polymorphism and risk of hepatocellular carcinoma in hepatitis C virus-infected patients

Talaat

Esmail²,

Elwakil³

et al. 2013

Chin J Cancer

View full text Add to dashboard Cite

Tumor necrosis factor-alpha (TNF-α) is an important cytokine in generating an immune response against infection with hepatitis C virus (HCV). The functions of TNF-α may be altered by single-nucleotide polymorphisms (SNPs) in its gene structure. We hypothesized that SNPs in TNF-α may be important in determining the outcome of an HCV infection. To test this hypothesis, we investigated the role of the polymorphism -308G/A, which is located in the promoter region of the TNF-α gene, in the progression of HCV infection in Egyptian patients using a quantitative real-time polymerase chain reaction (qRT-PCR). The distribution of this polymorphism and its impact on the serum level of TNF-α was compared between 90 HCV-infected patients [45 with HCV-induced cirrhosis and 45 with HCV-related hepatocellular carcinoma (HCC)] and 45 healthy Egyptian volunteers without any history of liver disease. Our results showed that at the TNF-α -308 position, the G/G allele was most common (78.5%) in the study population, with the G/A and A/A alleles occurring less frequently (13.3% and 8.1%, respectively). Frequencies of G/G, G/A, and A/A genotypes were 87%, 7%, and 6% in patients with liver cirrhosis and were 94%, 4%, and 2% in patients with HCC, respectively. Serum levels of TNF-α were significantly higher in HCV-infected patients than in healthy controls, indicating that the TNF-α -308 polymorphism does not influence the production of TNF-α. The serum level of TNF-α was positively correlated with HCV infection. Taken together, these findings suggest that the TNF-α -308 polymorphism may not be a host genetic factor associated with the severity of HCV infection, but may be an independent risk factor for HCC.

show abstract

Section: Discussionsupporting

confidence: 76%

Tumor necrosis factor-alpha-308G/A polymorphism and risk of hepatocellular carcinoma in hepatitis C virus-infected patients

Talaat

Esmail²,

Elwakil³

et al. 2013

Chin J Cancer

View full text Add to dashboard Cite

show abstract

“…In HCV infection, the influence of IL-10 genotypes either on different clinical features of liver disease or in the response to antiviral therapy has been evaluated in several studies: data are highly controversial with some studies showing a positive association and others denying such a link[18,22,23]. Taken together, the some investigation has shown that responsiveness to IFN-αtreatment in patients with chronic hepatitis C is closely linked to ATA haplotype of the IL-10 gene promoter.…”

Section: Discussionmentioning

confidence: 99%

Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis B to interferon alfa

Wang

Huang

Sun

et al. 2011

Virol J

View full text Add to dashboard Cite

In order to examine whether variation in interleukin-10 promoter polymorphism would predict the likelihood of sustain response of chronic hepatitis B to treatment with interferon alfa (IFN-α), the inheritance of 3 biallelic polymorphisms in the IL-10 gene promoter in patients with 52 chronic hepatitis B were determined by polymerase chain reaction (PCR)-bared techniques, restriction enzyme digestion or direct sequencing. The relationship to the outcome of antiviral therapy for chronic HBV infection was studied in 24 patients who had a virologically sustained response(SR) and in 28 non-responder(NR) to interferon alfa-2b and several IL-10 variants were more frequent among SR compared with NR. Carriage of the -592A allele, -592A/A genotype and -1082/-1819/-592 ATA haplotype was associated with SR. Our findings indicate that heterogeneity in the promoter region of the IL-10 gene has a role in determining the initial response of chronic hepatitis B to IFN-α therapy.

show abstract

“…Overall, 32 studies with a total of 5943 HCV cases (NR: 3380; SVR: 2563) and 2697 controls were included in the present study. 4 – 8 , 17 – 43 Included studies characteristics are summarized in Table 4 . Twenty-three studies were included for the rs1800896 (-1082 A/G) SNP, 4 – 8 , 17 , 19 , 22 – 26 , 29 – 37 , 39 , 41 17 for the rs1800871 (-819 C/T) SNP, 4 – 7 , 19 , 22 ,…”

Section: Resultsmentioning

confidence: 99%

Impact of IL-10 gene promoter polymorphisms on treatment response in HCV patients: A systematic review, a meta-analysis, and a meta-regression

Dhaouadi,

Riahi,

Ben Abdallah

et al. 2024

Int J Immunopathol Pharmacol

View full text Add to dashboard Cite

The impact of interleukin-10 (IL-10) gene promoter polymorphisms (SNPs) on treatment response in HCV patients was dissimilarly estimated. Hence, the aim of this meta-analysis was to robustly assess the effect of IL-10 SNPs on treatment response in HCV patients. An electronic literature search was carried out through PubMed, EMBASE, Web of science, and Scopus databases. Studies assessing the association between IL-10 polymorphisms and treatment response in HCV patients were included. Studies were excluded if genotype frequencies are not consistent with the Hardy–Weinberg Equilibrium (HWE) or in case of including patients with hepatitis B virus coinfection. Risk of bias in included studies was assessed using the Newcastle–Ottawa Scale. Meta-analyses were performed for the influence of IL-10 gene promoter SNPs (rs1800896 (-1082 A/G), rs1800871 (-819 C/T), and rs1800872 (-592 C/T)) and haplotypes on treatment response in HCV patients. Subgroup analyses, meta-regressions, publication bias assessment, and sensitivity analyses were also conducted. Overall, 32 studies with a total of 5943 HCV cases and 2697 controls were included in the present study. The -1082*G allele was significantly associated with increased risk of non-response (NR) to treatment, OR [95% CI] = 1.29 [1.1–1.51], p = .002. Besides, the rs1800872 -592*C allele was significantly associated with increased NR risk, OR [95% CI] = 1.22 [1.02–1.46], p = .03. Subgroup analysis showed that this association remained significant only in patients treated with PEG-IFN alone, p = .01. The -1082*G/-819*C/-592*C (GCC) haplotype was significantly associated with increased NR risk, OR [95% CI] = 1.62 [1.13–2.23], p = .009. Our results suggest that the IL-10 rs1800896 was associated with NR risk especially in North-African and Asian populations. Moreover, the IL-10 gene promoter -1082*G/-819*C/-592*C (GCC) haplotype which has been associated with higher production of IL-10, was significantly associated with increased NR risk.

show abstract

Interleukin‐1, interleukin‐10 and tumour necrosis factor‐alpha gene polymorphisms in hepatitis C virus infection: an investigation of the relationships with spontaneous viral clearance and response to alpha‐interferon therapy

Cited by 69 publications

References 43 publications

Tumor necrosis factor-alpha-308G/A polymorphism and risk of hepatocellular carcinoma in hepatitis C virus-infected patients

Tumor necrosis factor-alpha-308G/A polymorphism and risk of hepatocellular carcinoma in hepatitis C virus-infected patients

Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis B to interferon alfa

Impact of IL-10 gene promoter polymorphisms on treatment response in HCV patients: A systematic review, a meta-analysis, and a meta-regression

Contact Info

Product

Resources

About